TransCode Therapeutics, Inc. Announces Pricing of Public Offering
July 22, 2024 22:30 ET
|
TransCode Therapeutics, Inc.
Boston, MA — July 22, 2024 — TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed t
TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
July 22, 2024 16:07 ET
|
TransCode Therapeutics, Inc.
Boston, MA – July 22, 2024 – TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed t
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
June 10, 2024 07:00 ET
|
TransCode Therapeutics, Inc.
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
May 29, 2024 09:15 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
TransCode Therapeutics Open Letter to Shareholders
May 13, 2024 08:30 ET
|
TransCode Therapeutics, Inc.
An Open Letter to Shareholders regarding a Reverse Stock Split
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
April 15, 2024 09:00 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
TransCode Therapeutics Reports 2023 Results; Provides Business Update
April 03, 2024 09:10 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Reports 2023 Results; Provides Business Update
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
March 28, 2024 08:30 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
March 11, 2024 09:00 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
March 06, 2024 16:15 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress